Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Organogenesis Holdings Inc.NASDAQ: ORGO
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 13.2% from a year ago
Net receivables stood at $116.91M at the end of Q1 FY2026, up 13.2% from a year earlier and down 46.2% from the prior quarter. Over 3 fiscal years it compounded at +34.5% a year.
Context
- Net receivables amounted to 22.5% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +13.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 217.45M USD
- Year-over-year change
- +97.9%
- 4-year CAGR
- +27.4%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 217.45M | +97.9% |
| FY2024 | 2024-12-31 | 109.86M | +34.0% |
| FY2023 | 2023-12-31 | 82M | -8.3% |
| FY2022 | 2022-12-31 | 89.45M | +8.5% |
| FY2021 | 2021-12-31 | 82.46M | — |
Net Receivables vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +13.2% is the 2nd highest of 9, against a peer median of -2.7%.
- Net receivables amounts to 22.5% of total assets for ORGO, versus a peer median of 7.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Apr 2026 | $148.9M USD | +1.6% | -3.2% | 13.7% | |
| Mar 2026 | $132.35M USD | +62.8% | +60.8% | 28.6% | |
| Mar 2026 | $121.6M USD | -40.3% | -19.1% | 9.2% | |
| Mar 2026 | $116.91M USD | +13.2% | +34.5% | 22.5% | |
| Mar 2026 | $52.22M USD | +10.0% | +34.6% | 23.7% | |
| Feb 2026 | $45.55M USD | -7.0% | -8.6% | 17.5% | |
| Mar 2026 | $40.92M USD | -11.8% | +18.8% | 6.3% | |
| Mar 2026 | CA$31.91M CAD | +7.2% | +10.4% | 2.4% | |
| Mar 2026 | $4.5M USD | -37.4% | -58.4% | 2.1% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ORGO) | — | -2.7% | +3.6% | 7.7% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 113.93M | 102.48M | 104.34M | 135.57M | 93.68M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 82.46M | 89.45M | 82M | 109.86M | 217.45M |
| Inventory | 25.02M | 24.78M | 28.25M | 26.22M | 29.63M |
| Other Current Assets | 711K | 5.1M | 1.19M | 5.67M | 21.43M |
| Total Current Assets | 226.98M | 222.61M | 225.04M | 285.94M | 362.19M |
| Property, Plant & Equipment (Net) | 128.3M | 145.66M | 156.35M | 126.24M | 159.46M |
| Goodwill | 28.77M | 28.77M | 28.77M | 28.77M | 28.77M |
| Intangible Assets | 25.67M | 20.79M | 15.87M | 12.47M | 9.15M |
| Long-term Investments | 0 | 0 | 15.87M | 0 | 0 |
| Tax Assets | 31.99M | 30.01M | 28M | 39.46M | 29.96M |
| Other Non-current Assets | 1.54M | 1.52M | (9.88M) | 5.01M | 9.2M |
| Total Non-current Assets | 216.28M | 226.75M | 234.98M | 211.95M | 236.54M |
| Total Assets | 443.26M | 449.36M | 460.03M | 497.89M | 598.73M |
| Account Payables | 29.34M | 32.33M | 30.72M | 28.91M | 31.95M |
| Short-term Debt | 2.66M | 4.54M | 5.49M | 0 | 18.64M |
| Tax Payables | 1.16M | 2.63M | 2.8M | 4.29M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 29.44M | 9.33M | 22.17M | 25.29M | 49.53M |
| Total Current Liabilities | 82.71M | 75.02M | 80.51M | 77.48M | 100.12M |
| Long-term Debt | 70.77M | 66.23M | 60.75M | 0 | 50.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.56M | 1.12M | 1.21M | 894K | (49.51M) |
| Total Non-current Liabilities | 119.22M | 108.67M | 100.85M | 35.09M | 64.69M |
| Total Liabilities | 201.92M | 183.69M | 181.36M | 112.57M | 164.81M |
| Common Stock | 13K | 13K | 13K | 13K | 13K |
| Retained Earnings | (60.83M) | (45.3M) | (40.97M) | (40.11M) | (3.08M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 241.34M | 265.67M | 278.66M | 385.32M | 433.92M |
| Total Debt | 132.3M | 123.79M | 119.35M | 43.31M | 132.84M |
| Net Debt | 18.37M | 21.31M | 15.01M | (92.26M) | 39.17M |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.